Biogen criticized in the US over price of new Alzheimer's drug

Bloomberg News reports that treating 1 million patients will cost around USD 57bn annually according to an estimate made by the Kaiser Family Foundation.

Photo: Steven Senne/AP/Ritzau Scanpix

The price tag of Biogen's new Alzheimer's medication Aduhelm has raised criticism and concern in the US. Soon, authorities will decide the extent of the available support schemes and the patient groups that will be offered the medication, according to Bloomberg News.

The price for one year of treatment has been set at USD 56,000. Moreover, patients will need regular scans to monitor the effect of the treatment and potential side effects. Thus, this can quickly turn into a costly affair.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs